Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 361 to 364 of 364 entries
Sorted by: Best Match Show Resources per page
Association of Statins and 28-Day Mortality Rates in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

The Journal of infectious diseases

Memel ZN, Lee JJ, Foulkes AS, Chung RT, Thaweethai T, Bloom PP.
PMID: 34665852
J Infect Dis. 2022 Jan 05;225(1):19-29. doi: 10.1093/infdis/jiab539.

BACKGROUND: Statins may be protective in severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection. The aim of the current study was to evaluate the effect of in-hospital statin use on 28-day mortality rates and intensive care unit (ICU) admission...

Cite
Memel ZN, Lee JJ, Foulkes AS, et al. Association of Statins and 28-Day Mortality Rates in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis. 2022;225(1):19-29doi: 10.1093/infdis/jiab539.
Memel, Z. N., Lee, J. J., Foulkes, A. S., Chung, R. T., Thaweethai, T., & Bloom, P. P. (2022). Association of Statins and 28-Day Mortality Rates in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. The Journal of infectious diseases, 225(1), 19-29. https://doi.org/10.1093/infdis/jiab539
Memel, Zoe N, et al. "Association of Statins and 28-Day Mortality Rates in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection." The Journal of infectious diseases vol. 225,1 (2022): 19-29. doi: https://doi.org/10.1093/infdis/jiab539
Memel ZN, Lee JJ, Foulkes AS, Chung RT, Thaweethai T, Bloom PP. Association of Statins and 28-Day Mortality Rates in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis. 2022 Jan 05;225(1):19-29. doi: 10.1093/infdis/jiab539. PMID: 34665852; PMCID: PMC8586726.
Copy Download .nbib Format: NLM
Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain.

JACC. CardioOncology

Costello BT, Roberts TJ, Howden EJ, Bigaran A, Foulkes SJ, Beaudry RI, Janssens K, Haykowsky MJ, Antill Y, Nightingale S, Loi S, La Gerche A.
PMID: 34396194
JACC CardioOncol. 2019 Dec 17;1(2):298-301. doi: 10.1016/j.jaccao.2019.09.002. eCollection 2019 Dec.

No abstract available.

Cite
Costello BT, Roberts TJ, Howden EJ, et al. Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain. JACC CardioOncol. 2019;1(2):298-301doi: 10.1016/j.jaccao.2019.09.002.
Costello, B. T., Roberts, T. J., Howden, E. J., Bigaran, A., Foulkes, S. J., Beaudry, R. I., Janssens, K., Haykowsky, M. J., Antill, Y., Nightingale, S., Loi, S., & La Gerche, A. (2019). Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain. JACC. CardioOncology, 1(2), 298-301. https://doi.org/10.1016/j.jaccao.2019.09.002
Costello, Benedict T, et al. "Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain." JACC. CardioOncology vol. 1,2 (2019): 298-301. doi: https://doi.org/10.1016/j.jaccao.2019.09.002
Costello BT, Roberts TJ, Howden EJ, Bigaran A, Foulkes SJ, Beaudry RI, Janssens K, Haykowsky MJ, Antill Y, Nightingale S, Loi S, La Gerche A. Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain. JACC CardioOncol. 2019 Dec 17;1(2):298-301. doi: 10.1016/j.jaccao.2019.09.002. eCollection 2019 Dec. PMID: 34396194; PMCID: PMC8352105.
Copy Download .nbib Format: NLM
Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma.

Cancer treatment and research communications

Yoon JY, de Kock L, Stewart CJR, McCluggage WG, Foulkes WD, Clarke BA, Rouzbahman M.
PMID: 33838572
Cancer Treat Res Commun. 2021;27:100363. doi: 10.1016/j.ctarc.2021.100363. Epub 2021 Mar 31.

BACKGROUND: The uterus is one of the most dynamic organs in the human body, and this dynamic homeostasis is supported by endometrial stem/progenitor cells (ES/PCs), which are heterogeneous in their phenotype and degree of differentiation. ES/PCs are generally localized...

Cite
Yoon JY, de Kock L, Stewart CJR, et al. Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma. Cancer Treat Res Commun. 2021;27:100363doi: 10.1016/j.ctarc.2021.100363.
Yoon, J. Y., de Kock, L., Stewart, C. J. R., McCluggage, W. G., Foulkes, W. D., Clarke, B. A., & Rouzbahman, M. (2021). Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma. Cancer treatment and research communications, 27100363. https://doi.org/10.1016/j.ctarc.2021.100363
Yoon, Ju-Yoon, et al. "Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma." Cancer treatment and research communications vol. 27 (2021): 100363. doi: https://doi.org/10.1016/j.ctarc.2021.100363
Yoon JY, de Kock L, Stewart CJR, McCluggage WG, Foulkes WD, Clarke BA, Rouzbahman M. Endometrial Stem/Progenitor cell (ES/PC) Marker Expression Profile in Adenosarcoma and Endometrial Stromal Sarcoma. Cancer Treat Res Commun. 2021;27:100363. doi: 10.1016/j.ctarc.2021.100363. Epub 2021 Mar 31. PMID: 33838572.
Copy Download .nbib Format: NLM
Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes.

JAMA oncology

Goudie C, Witkowski L, Cullinan N, Reichman L, Schiller I, Tachdjian M, Armstrong L, Blood KA, Brossard J, Brunga L, Cacciotti C, Caswell K, Cellot S, Clark ME, Clinton C, Coltin H, Felton K, Fernandez CV, Fleming AJ, Fuentes-Bolanos N, Gibson P, Grant R, Hammad R, Harrison LW, Irwin MS, Johnston DL, Kane S, Lafay-Cousin L, Lara-Corrales I, Larouche V, Mathews N, Meyn MS, Michaeli O, Perrier R, Pike M, Punnett A, Ramaswamy V, Say J, Somers G, Tabori U, Thibodeau ML, Toupin AK, Tucker KM, van Engelen K, Vairy S, Waespe N, Warby M, Wasserman JD, Whitlock JA, Sinnett D, Jabado N, Nathan PC, Shlien A, Kamihara J, Deyell RJ, Ziegler DS, Nichols KE, Dendukuri N, Malkin D, Villani A, Foulkes WD.
PMID: 34617981
JAMA Oncol. 2021 Dec 01;7(12):1806-1814. doi: 10.1001/jamaoncol.2021.4536.

IMPORTANCE: Prompt recognition of a child with a cancer predisposition syndrome (CPS) has implications for cancer management, surveillance, genetic counseling, and cascade testing of relatives. Diagnosis of CPS requires practitioner expertise, access to genetic testing, and test result interpretation....

Cite
Goudie C, Witkowski L, Cullinan N, et al. Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. JAMA Oncol. 2021;7(12):1806-1814doi: 10.1001/jamaoncol.2021.4536.
Goudie, C., Witkowski, L., Cullinan, N., Reichman, L., Schiller, I., Tachdjian, M., Armstrong, L., Blood, K. A., Brossard, J., Brunga, L., Cacciotti, C., Caswell, K., Cellot, S., Clark, M. E., Clinton, C., Coltin, H., Felton, K., Fernandez, C. V., Fleming, A. J., Fuentes-Bolanos, N., Gibson, P., Grant, R., Hammad, R., Harrison, L. W., Irwin, M. S., Johnston, D. L., Kane, S., Lafay-Cousin, L., Lara-Corrales, I., Larouche, V., Mathews, N., Meyn, M. S., Michaeli, O., Perrier, R., Pike, M., Punnett, A., Ramaswamy, V., Say, J., Somers, G., Tabori, U., Thibodeau, M. L., Toupin, A. K., Tucker, K. M., van Engelen, K., Vairy, S., Waespe, N., Warby, M., Wasserman, J. D., Whitlock, J. A., Sinnett, D., Jabado, N., Nathan, P. C., Shlien, A., Kamihara, J., Deyell, R. J., Ziegler, D. S., Nichols, K. E., Dendukuri, N., Malkin, D., Villani, A., & Foulkes, W. D. (2021). Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. JAMA oncology, 7(12), 1806-1814. https://doi.org/10.1001/jamaoncol.2021.4536
Goudie, Catherine, et al. "Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes." JAMA oncology vol. 7,12 (2021): 1806-1814. doi: https://doi.org/10.1001/jamaoncol.2021.4536
Goudie C, Witkowski L, Cullinan N, Reichman L, Schiller I, Tachdjian M, Armstrong L, Blood KA, Brossard J, Brunga L, Cacciotti C, Caswell K, Cellot S, Clark ME, Clinton C, Coltin H, Felton K, Fernandez CV, Fleming AJ, Fuentes-Bolanos N, Gibson P, Grant R, Hammad R, Harrison LW, Irwin MS, Johnston DL, Kane S, Lafay-Cousin L, Lara-Corrales I, Larouche V, Mathews N, Meyn MS, Michaeli O, Perrier R, Pike M, Punnett A, Ramaswamy V, Say J, Somers G, Tabori U, Thibodeau ML, Toupin AK, Tucker KM, van Engelen K, Vairy S, Waespe N, Warby M, Wasserman JD, Whitlock JA, Sinnett D, Jabado N, Nathan PC, Shlien A, Kamihara J, Deyell RJ, Ziegler DS, Nichols KE, Dendukuri N, Malkin D, Villani A, Foulkes WD. Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. JAMA Oncol. 2021 Dec 01;7(12):1806-1814. doi: 10.1001/jamaoncol.2021.4536. PMID: 34617981; PMCID: PMC8498936.
Copy Download .nbib Format: NLM
Showing 361 to 364 of 364 entries